DECIPHER is a retrospective multicentre observational cohort study using data collected across UKCHART sites. The study will evaluate the impact of ethnicity, socioeconomic deprivation and comorbidity burden on treatment delivery and outcomes in adults diagnosed with DLBCL between 2021 and 2025.
Adults aged ≥18 years.
Newly diagnosed DLBCL.
Managed within participating UKCHART sites.
Transformed lymphoma.
Insufficient linkage data.
Data will be collected retrospectively by the 21 individual trusts which make up UKCHART. The population catchment is around 18 million.
Cohort
Retrospective
Not listed
Treatment completion
Delivered versus planned number of frontline chemoimmunotherapy cycles
Dose intensity reduction
Occurrence and magnitude (%) of chemotherapy dose reductions, particularly reductions \>25% from planned treatment
Overall Survival (OS)
Measured as time from diagnosis (or treatment start, as defined in the SAP) to death from any cause
Progression-Free Survival (PFS)
Measured as time from diagnosis/treatment initiation to disease progression, relapse, or death.
Stage at Diagnosis
Measured using Ann Arbor stage recorded at diagnosis
Time to Treatment Initiation
Measured as the interval between diagnosis and commencement of first-line treatment.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
